mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Report

mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Application, By Indication, By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report ID: GVR-4-68040-083-7
  • Number of Pages: 144
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2023
  • Industry: Healthcare

Market Segmentation

  • mRNA Therapeutics CDMO Application Outlook (Revenue, USD Million, 2018 - 2030)
    • Viral Vaccines
    • Protein Replacement Therapies
    • Cancer Immunotherapies
  • mRNA Therapeutics CDMO Indication Outlook (Revenue, USD Million, 2018 - 2030)
    • Infectious Diseases
    • Metabolic & Genetic Diseases
    • Cardiovascular & Cerebrovascular Diseases
  • mRNA Therapeutics CDMO End-use Outlook (Revenue, USD Million, 2018 - 2030)
    • Biotech Companies
    • Pharmaceutical companies
    • Government & Academic Research Institutes
  • mRNA Therapeutics CDMO Regional Outlook (Revenue, USD Million, 2018 - 2030)
    • North America
      • North America Application Outlook (Revenue, USD Million, 2018 - 2030)
        • Viral Vaccines
        • Protein Replacement Therapies
        • Cancer Immunotherapies
      • North America Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Infectious Diseases
        • Metabolic & Genetic Diseases
        • Cardiovascular & Cerebrovascular Diseases
      • North America End-Use Outlook (Revenue in USD Million, 2018 - 2030)
        • Biotech Companies
        • Pharmaceutical companies
        • Government & Academic Research Institutes
      • U.S.
        • U.S. Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • U.S. Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • U.S. End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
      • Canada
        • Canada Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • Canada Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • Canada End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
    • Europe
      • Europe Application Outlook (Revenue, USD Million, 2018 - 2030)
        • Viral Vaccines
        • Protein Replacement Therapies
        • Cancer Immunotherapies
      • Europe Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Infectious Diseases
        • Metabolic & Genetic Diseases
        • Cardiovascular & Cerebrovascular Diseases
      • Europe End-Use Outlook (Revenue in USD Million, 2018 - 2030)
        • Biotech Companies
        • Pharmaceutical companies
        • Government & Academic Research Institutes
      • UK
        • UK Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • UK Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • UK End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
      • Germany
        • Germany Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • Germany Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • Germany End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
      • France
        • France Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • France Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • France End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
      • Italy
        • Italy Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • Italy Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • Italy End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
      • Spain
        • Spain Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • Spain Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • Spain End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
      • Sweden
        • Sweden Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • Sweden Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • Sweden End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
      • Denmark
        • Denmark Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • Denmark Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • Denmark End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
      • Norway
        • Norway Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • Norway Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • Norway End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
    • Asia Pacific
      • Asia Pacific Application Outlook (Revenue, USD Million, 2018 - 2030)
        • Viral Vaccines
        • Protein Replacement Therapies
        • Cancer Immunotherapies
      • Asia Pacific Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Infectious Diseases
        • Metabolic & Genetic Diseases
        • Cardiovascular & Cerebrovascular Diseases
      • Asia Pacific End-Use Outlook (Revenue in USD Million, 2018 - 2030)
        • Biotech Companies
        • Pharmaceutical companies
        • Government & Academic Research Institutes
      • Japan
        • Japan Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • Japan Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • Japan End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
      • China
        • China Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • China Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • China End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
      • India
        • India Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • India Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • India End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
      • South Korea
        • South Korea Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • South Korea Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • South Korea End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
      • Australia
        • Australia Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • Australia Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • Australia End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
      • Indonesia
        • Indonesia Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • Indonesia Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • Indonesia End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
    • Latin America
      • Latin America Application Outlook (Revenue, USD Million, 2018 - 2030)
        • Viral Vaccines
        • Protein Replacement Therapies
        • Cancer Immunotherapies
      • Latin America Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Infectious Diseases
        • Metabolic & Genetic Diseases
        • Cardiovascular & Cerebrovascular Diseases
      • Latin America End-Use Outlook (Revenue in USD Million, 2018 - 2030)
        • Biotech Companies
        • Pharmaceutical companies
        • Government & Academic Research Institutes
      • Brazil
        • Brazil Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • Brazil Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • Brazil End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
      • Mexico
        • Mexico Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • Mexico Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • Mexico End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
      • Argentina
        • Argentina Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • Argentina Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • Argentina End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
    • Middle East and Africa
      • Middle East and Africa Application Outlook (Revenue, USD Million, 2018 - 2030)
        • Viral Vaccines
        • Protein Replacement Therapies
        • Cancer Immunotherapies
      • Middle East and Africa Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Infectious Diseases
        • Metabolic & Genetic Diseases
        • Cardiovascular & Cerebrovascular Diseases
      • Middle East and Africa End-Use Outlook (Revenue in USD Million, 2018 - 2030)
        • Biotech Companies
        • Pharmaceutical companies
        • Government & Academic Research Institutes
      • South Africa
        • South Africa Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • South Africa Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • South Africa End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
      • Saudi Arabia
        • Saudi Arabia Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • Saudi Arabia Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • Saudi Arabia End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
      • UAE
        • UAE Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • UAE Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • UAE End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institutes
      • Kuwait
        • Kuwait Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Viral Vaccines
          • Protein Replacement Therapies
          • Cancer Immunotherapies
        • Kuwait Indication Outlook (Revenue in USD Million, 2018 - 2030)
          • Infectious Diseases
          • Metabolic & Genetic Diseases
          • Cardiovascular & Cerebrovascular Diseases
        • Kuwait End-Use Outlook (Revenue in USD Million, 2018 - 2030)
          • Biotech Companies
          • Pharmaceutical companies
          • Government & Academic Research Institut

Report content

Qualitative Analysis

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Market size
  • Growth prospects
  • Porter’s analysis
  • PESTEL analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis

  • Market size, estimates, and forecast from 2018 to 2030
  • Market estimates and forecast for product segments up to 2030
  • Regional market size and forecast for product segments up to 2030
  • Market estimates and forecast for application segments up to 2030
  • Regional market size and forecast for application segments up to 2030
  • Company financial performance
What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon